semaglutide weight loss treatment branson Prescription for in Missouri The 2026 Brandon GLP-1 Report:

Patients should inform their healthcare provider about all ongoing treatments

It is crucial for healthcare providers to carefully consider these dosages, as compounded medications lack the standardized testing of commercially available products, necessitating vigilant monitoring for efficacy and safety

Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health

A malnourished mother on any weight loss medication, GLP-1 or otherwise, poses significant risk